摘要
目的探讨重组人脑利钠肽联合沙库巴曲缬沙坦钠对射血分数降低心力衰竭的治疗效果。方法选择2021年1月至2022年6月揭阳市人民医院心内科60例射血分数降低的心力衰竭患者作为研究对象,按照随机数字表法分为观察组和对照组,各30例。两组入院均接受基础治疗,对照组在基础治疗上联合硝普钠和培哚普利叔丁胺片,观察组在基础上联合重组人脑利钠肽和沙库巴曲缬沙坦钠,比较两组疗效、心功能、运动耐力、不良反应和再住院率。结果观察组治疗后左室射血分数(LVEF)和6分钟步行实验(6MWT)高于对照组,左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)和N末端脑钠肽原(NT-proBNP)低于对照组,差异有统计学意义(P<0.05),观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05),两组不良反应总发生率和再住院率比较,差异无统计学意义(P>0.05)。结论重组人脑利钠肽联合沙库巴曲缬沙坦钠治疗射血分数降低的心力衰竭效果良好且能够改善患者心功能,提高运动耐力,具有一定安全性,值得应用。
Objective To investigate the therapeutic effect of Recombinant Human Brain Natriuretic Peptide combined with Salkubactril Valsartan Sodium on reducing ejection fraction of heart failure.Methods Sixty patients with heart failure with decreased ejection fraction in the Department of Cardiology of Jieyang People's Hospital from January 2021 to June 2022 were selected as research objects,and they were divided into observation group and control group according to random number table method,with 30 cases in each group.The two groups were admitted to the hospital and received basic treatment.The control group was combined with Sodium Nitroprusside and Perindopril Tert-Butylamine Tablets,and the observation group was combined with Recombinant Human Brain Natriuretic Peptide and Salkubactril Valsartan Sodium on the basis of basic treatment.The efficacy,cardiac function,exercise endurance,adverse reactions and readmission rate of the two groups were compared.Results After treatment,the left ventricular ejection fraction(LVEF)level and 6-minute walking experiment(6MWT)in the observation group were higher than those in the control group,but the left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)and N-terminal brain natriuretic peptide(NT-proBNP)level in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).There were no differences in the rates of total incidence of adverse reactions and readmissions between the two groups(P>0.05).Conclusion Recombinant Human Brain Natriuretic Peptide combined with Salkubactril Valsartan Sodium in the treatment of heart failure with reduced ejection fraction has a good effect and can improve the cardiac function of patients,improve exercise endurance,has a certain safety,worthy of application.
作者
邝鸿生
纪伟彪
黄小妍
纪炳能
吴琼苗
郑烈辉
KUANG Hongsheng;JI Weibiao;HUANG Xiaoyan;JI Bingneng;WU Qiongmiao;ZHENG Liehui(Department of Cardiovascular Medicine,Jieyang People's Hospital,Guangdong Province,Jieyang 522000,China;Department of General Medicine,Jieyang People's Hospital,Guangdong Province,Jieyang 522000,China;Department of Teaching&Research,Jieyang People's Hospital,Guangdong Province,Jieyang 522000,China;Department of Neurosurgery,Jieyang People's Hospital,Guangdong Province,Jieyang 522000,China)
出处
《中国当代医药》
CAS
2023年第16期71-74,78,共5页
China Modern Medicine
基金
广东省揭阳市科技计划项目(ylxm006)。
关键词
心力衰竭
射血分数降低
重组人脑利钠肽
沙库巴曲缬沙坦钠
预后
Heart failure
Ejection fraction decreased
Recombinant Human Brain Natriuretic Peptide
Salkubactril Valsartan Sodium
Prognosis
